Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
Publication Date Feb 2014
Publisher GlobalData
Product Type Report
Pages 328
Single User License help $ 9995.00
Site User License help $ 19990.00
Corporate User License help $ 29985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

During the forecast period from 2012–2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Overall, major barriers to the growth of the UC market include:
Remicade and Humira losing patent protection in the mid-forecast
Austerity measures favoring generic prescribing
Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US
In 2012, GlobalData estimates that the global UC market reached $4.2 billion across the 10 healthcare markets covered in our forecast: the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of the forecast period, in 2022, sales across these markets will grow steadily to reach $6.6 billion, representing a Compound Annual Growth Rate (CAGR) of 4.8% over the 10-year timeframe .

Scope
Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs.
Analysis of the current and future market competition in the global UC therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Model only available with site and global license purchases.

Key Findings
The UC market has predominantly been driven by two TNF blockers, namely J&J’s Remicade and AbbVie’s Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda’s Entyvio imminently entering the market in 2014 and J&J’s Simponi launching in 2014 as well, stealing market share from Humira and Remicade.
Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion’s Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market.
During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals’ Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer’s Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis.

Key Questions Answered in this Report
How will the UC market (sales and patient numbers) evolve over the 10-year forecast period from 2012 to 2022?
Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
How will the launch of late-stage pipeline therapies such as Entyvio and Kappaproct shape the future treatment landscape?
What are the remaining unmet needs and opportunities for drug developers within the UC market?

Key Benefits
Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global UC therapeutics markets.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics markets in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global UC therapeutics markets from 2012-2022.
Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned
J&J
AbbVie
Takeda
Warner Chilcott
Salix/Santarus
Shire
Ferring
Pfizer
InDeX Pharmaceuticals


Report at a Glance

Number of Pages – 328
Number of Tables – 144
Number of Figures – 30
Number of Companies Mentioned – 9
Number of Marketed and Pipeline Products Mentioned – 14
Number of KOL interviews – 9
Major Pipeline Products Mentioned – 3 Phase III/Filed products
Markets Covered – US, France, Germany, Italy, Spain, UK, Japan, Canada, China, India

List Of Tables

Table 1: Ulcerative Colitis: Key Metrics in the 10 Major Pharmaceutical Markets, 2012–2022    16

Table 2: Genetic Factors That Confer a Predisposition to UC    30

Table 3: Typical Symptoms of UC    32

Table 4: Strongest Putative Risk Factors for UC    36

Table 5: Prevalence of UC in the US    41

Table 6: Incidence of UC in the 5EU    42

Table 7: Prevalence of UC in the 5EU    43

Table 8: 10MM, Sources of UC Incidence Data Used in the Epidemiological Forecast    50

Table 9: 10MM, Sources of UC Prevalence Data Used in the Epidemiological Forecast    51

Table 10: 10MM, Incident Cases of UC, Ages =10 Years, Both Sexes, N, Select Years, 2012–2022    65

Table 11: 10MM, Incident Cases of UC, By Age, Both Sexes, N (Row %), 2012    67

Table 12: 10MM, Incident Cases of UC, By Sex, Ages =10 Years, N (Row %), 2012    69

Table 13: 10MM, Prevalent Cases of UC, Ages =10 Years, Both Sexes, N, Select Years, 2012–2022    72

Table 14: 10MM, Prevalent Cases of UC, By Age, Both Sexes, N (Row %), 2012    74

Table 15: 10MM, Prevalent Cases of UC, By Sex, Ages =10 Years, N (Row %), 2012    76

Table 16: Truelove and Witts UC Severity Index    83

Table 17: UCDAI    84

Table 18: Treatment Guidelines for UC Used in the 10MM    85

Table 19: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013    86

Table 20: UC Management Country Profile – US    92

Table 21: UC Management Country Profile – France    94

Table 22: UC Management Country Profile – Germany    97

Table 23: UC Management Country Profile – Italy    100

Table 24: UC Management Country Profile – Spain    102

Table 25: UC Management Country Profile – UK    105

Table 26: UC Management Country Profile – Japan    107

Table 27: Country Profile – Canada    110

Table 28: UC Management Country Profile – China    112

Table 29: UC Management Country Profile – India    115

Table 30: Leading Treatments for UC, 2014    118

Table 31: Product Profile – Remicade    121

Table 32: Remicade SWOT Analysis, 2014    125

Table 33: Global Sales Forecasts ($m) for Remicade, 2012–2022    126

Table 34: Product Profile – Humira    128

Table 35: Humira Efficacy in the ULTRA 2 Trial    129

Table 36: Product Efficacy Comparison – Humira vs. Remicade    129

Table 37: Humira SWOT Analysis, 2014    131

Table 38: Global Sales Forecasts ($m) for Humira, 2012–2022    132

Table 39: Product Profile – Simponi    134

Table 40: Simponi SWOT Analysis, 2014    136

Table 41: Global Sales Forecasts ($m) for Simponi, 2012–2022    137

Table 42: Product Profile – Apriso    139

Table 43: Apriso SWOT Analysis, 2014    141

Table 44: Global Sales Forecasts ($m) for Apriso, 2012–2022    142

Table 45: Product Profile – Asacol HD    144

Table 46: Asacol HD SWOT Analysis, 2014    147

Table 47: Global Sales Forecasts ($m) for Asacol HD, 2012–2022    148

Table 48: Product Profile – Lialda    149

Table 49: Lialda SWOT Analysis, 2014    151

Table 50: Global Sales Forecasts ($m) for Lialda, 2012–2022    152

Table 51: Product Profile – Pentasa    153

Table 52: Pentasa SWOT Analysis, 2014    155

Table 53: Global Sales Forecasts ($m) for Pentasa, 2012–2022    156

Table 54: Product Profile – Colazal    157

Table 55: Colazal SWOT Analysis, 2014    159

Table 56: Global Sales Forecasts ($m) for Colazal, 2012–2022    160

Table 57: Product Profile – Giazo    161

Table 58: Giazo SWOT Analysis, 2014    163

Table 59: Global Sales Forecasts ($m) for Giazo, 2012–2022    164

Table 60: Product Profile – sfRowasa    165

Table 61: sfRowasa SWOT Analysis, 2014    166

Table 62: Global Sales Forecasts ($m) for sfRowasa, 2012–2022    167

Table 63: Product Profile – Uceris    168

Table 64: Uceris SWOT Analysis, 2014    170

Table 65: Global Sales Forecasts ($m) for Uceris, 2012–2022    171

Table 66: Summary of Other Immunomodulators for UC, 2013    172

Table 67: Biosimilars Pipeline, 2013    174

Table 68: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2012–2022    177

Table 69: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2012–2022    177

Table 70: Global Sales Forecasts ($m) for Golimumab Biosimilars, 2012–2022    178

Table 71: Overall Unmet Needs – Current Level of Attainment    179

Table 72: Corticosteroid Long-Term Side Effects    182

Table 73: Clinical Unmet Needs in UC – Gap Analysis, 2013    185

Table 74: Prognostic Markers in UC    186

Table 75: UC – Clinical Trials by Phase and Status, 2014    189

Table 76: UC – Pre-Registration and Phase III Pipeline, 2014    189

Table 77: Comparison of Therapeutic Classes in Development for UC, 2014    190

Table 78: Product Profile – Entyvio    193

Table 79: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC    194

Table 80: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC    195

Table 81: Most Common Adverse Events with Vedolizumab in the GEMINI I Study    196

Table 82: Entyvio SWOT Analysis, 2014    199

Table 83: Global Sales Forecasts ($m) for Entyvio, 2012–2022    201

Table 84: Product Profile – Xeljanz    202

Table 85: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC    203

Table 86: Most Common Adverse Events in the Phase IIa Trial of Xeljanz    205

Table 87: Xeljanz SWOT Analysis, 2014    207

Table 88: Global Sales Forecasts ($m) for Xeljanz, 2012–2022    208

Table 89: Product Profile – Kappaproct    209

Table 90: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC    210

Table 91: Kappaproct SWOT Analysis, 2014    212

Table 92: Global Sales Forecasts ($m) for Kappaproct, 2012–2022    213

Table 93: Key Companies in the UC Market, 2012–2022    215

Table 94: J&J’s UC Portfolio Assessment, 2014    221

Table 95: J&J’s SWOT Analysis in UC, 2014    222

Table 96: AbbVie’s UC Portfolio Assessment, 2014    223

Table 97: AbbVie’s UC SWOT Analysis, 2014    224

Table 98: Takeda Pharmaceuticals’ UC Portfolio Assessment, 2014    225

Table 99: Takeda’s UC SWOT Analysis, 2014    226

Table 100: Warner Chilcott’s UC Portfolio Assessment, 2014    227

Table 101: Warner Chilcott’s UC SWOT Analysis, 2014    228

Table 102: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013    229

Table 103: Salix Pharmaceuticals/Santarus UC SWOT Analysis, 2014    230

Table 104: Shire Pharmaceuticals’ UC Portfolio Assessment, 2014    231

Table 105: Shire Pharmaceuticals’ UC SWOT Analysis, 2014    231

Table 106: Ferring Pharmaceuticals’ UC Portfolio Assessment, 2013    232

Table 107: Ferring Pharmaceutical’s UC SWOT Analysis, 2014    233

Table 108: Pfizer’s UC Portfolio Assessment, 2014    234

Table 109: Pfizer’s UC SWOT Analysis, 2014    235

Table 110: InDeX Pharmaceuticals’ UC Portfolio Assessment, 2013    236

Table 111: InDeX Pharmaceuticals’ UC SWOT Analysis, 2014    237

Table 112: Global Sales Forecasts ($m) for UC, 2012–2022    240

Table 113: Global UC Market – Drivers and Barriers, 2012–2022    243

Table 114: Sales Forecasts ($m) for UC in the US, 2012–2022    249

Table 115: Key Events Impacting Sales for UC in the US, 2012–2022    251

Table 116: UC Market in the US – Drivers and Barriers, 2012–2022    251

Table 117: Sales Forecasts ($m) for UC in France, 2012–2022    255

Table 118: Key Events Impacting Sales for UC in France, 2012–2022    257

Table 119: UC Market in France – Drivers and Barriers, 2012–2022    258

Table 120: Sales Forecasts ($m) for UC in Germany, 2012–2022    263

Table 121: Key Events Impacting Sales for UC in Germany, 2012–2022    265

Table 122: UC Market in Germany – Drivers and Barriers, 2012–2022    265

Table 123: Sales Forecasts ($) for UC in Italy, 2012–2022    269

Table 124: Key Events Impacting Sales for UC in Italy, 2012–2022    271

Table 125: UC Market in Italy – Drivers and Barriers, 2012–2022    271

Table 126: Sales Forecasts ($m) for UC in Spain, 2012–2022    275

Table 127: Key Events Impacting Sales for UC in Spain, 2012–2022    277

Table 128: UC Market in Spain – Drivers and Barriers, 2012–2022    277

Table 129: Sales Forecasts ($m) for UC in the UK, 2012–2022    280

Table 130: Key Events Impacting Sales for UC in the UK, 2012–2022    283

Table 131: UC Market in the UK – Drivers and Barriers, 2012–2022    283

Table 132: Sales Forecasts ($) for UC in Japan, 2012–2022    287

Table 133: Key Events Impacting Sales for UC in Japan, 2012–2022    289

Table 134: UC Market in Japan – Drivers and Barriers, 2012–2022    289

Table 135: Sales Forecasts ($m) for UC in Canada, 2012–2022    293

Table 136: Key Events Impacting Sales for UC in Canada, 2012–2022    295

Table 137: UC Market in Canada – Drivers and Barriers, 2012–2022    296

Table 138: Sales Forecasts ($) for UC in China, 2012–2022    298

Table 139: Key Events Impacting Sales for UC in China, 2012–2022    300

Table 140: UC Market in China – Drivers and Barriers, 2012–2022    300

Table 141: Sales Forecasts ($) for UC in India, 2012–2022    302

Table 142: Key Events Impacting Sales for UC in India, 2012–2022    304

Table 143: UC Market in India – Drivers and Barriers, 2012–2022    305

Table 144: Key launches for Ulcerative Colitis , 2012-2022    324

Table 145: Key Patent Expiries    325

Table 146: Annual Cost of Therapy for 5-ASAs ($)    328

Table 147: Physicians Surveyed, By Country    331

List Of Figures

Figure 1: Global UC Sales by Region, 2012–2022    19

Figure 2: Company Portfolio Gap Analysis in UC, 2012–2022    22

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in UC, 2012–2022    25

Figure 4: Cellular Mechanisms Involved in the Pathogenesis of UC    32

Figure 5: Olmsted Country, Minnesota, US, Age- and Sex-Adjusted Incidence of UC, Cases per 100,000 Population, 1940–2000    40

Figure 6: Canada, Incidence and Prevalence of UC, Cases per 100,000 Population, 1990–2001    46

Figure 7: Hong Kong, China, Crude Incidence and Prevalence of UC, Cases per 100,000 Population, 1997–2006    48

Figure 8: 10MM, Incident Cases of UC, Ages = 10 Years, Both Sexes, N, 2012–2022    66

Figure 9: 10MM, Incident Cases of UC, By Age, Both Sexes, N, 2012    68

Figure 10: 10MM, Incident Cases of UC, By Sex, Ages =10 Years, N, 2012    70

Figure 11: 10MM, Age-Standardized Incidence of UC, Ages =10 Years, Both Sexes, Cases per 100,000 Population, 2012    71

Figure 12: 10MM, Prevalent Cases of UC, Ages =10 Years, Both Sexes, N, 2012–2022    73

Figure 13: 10MM, Prevalent Cases of UC, By Sex, Ages = 10 Years, N, 2012    75

Figure 14: 10MM, Prevalent Cases of UC, By Sex, Ages =10 Years, N, 2012    77

Figure 15: 10MM, Age-Standardized Prevalence of UC, Ages =10 Years, Both Sexes, %, 2012    78

Figure 16: UC Disease Management Flowchart    89

Figure 17: UC Therapeutics – Clinical Trials by Country, 2014    188

Figure 18: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012–2022    190

Figure 19: Company Portfolio Gap Analysis in UC, 2012–2022    217

Figure 20: Global Sales for UC by Region, 2012 (Total: $m)–2022 (Total: $m)    242

Figure 21: Sales for UC in the US by Drug Class, 2012–2022    250

Figure 22: Sales for UC in France by Drug Class, 2012–2022    257

Figure 23: Sales for UC in Germany by Drug Class, 2012–2022    264

Figure 24: Sales for UC in Italy by Drug Class, 2012–2022    270

Figure 25: Sales for UC in Spain by Drug Class, 2012–2022    276

Figure 26: Sales for UC in the UK by Drug Class, 2012–2022    282

Figure 27: Sales for UC in Japan by Drug Class, 2012–2022    288

Figure 28: Sales for UC in Canada by Drug Class, 2012–2022    295

Figure 29: Sales for UC in China by Drug Class, 2012–2022    299

Figure 30: Sales for UC in India by Drug Class, 2012–2022    304

Title Date Price
1300 Smiles Limited (ONT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
By GlobalData
Summary1300 Smiles Limited (1300 Smiles) is a dental service company based in Australia. The company provides dentistry services to patients that include dental surgeries, practice management and othe ...Read More
Jan 2013 $250.00
2013 Deep Research Report on China Human Tetanus Immunoglobulin Industry
By QYResearch
2013 Deep Research Report on China Human Tetanus Immunoglobulin Industry is a professional and depth research report on China Human Tetanus Immunoglobulin industry. The report firstly introduced Human ...Read More
Apr 2013 $2000.00
2013 Deep Research Report on Global and China MBR Membrane Industry
By QYResearch
2013 Deep Research Report on Global and China MBR Membrane Industry is a  professional and depth research report on global and China MBR membrane industry. Firstly, the report has introduced MBR ...Read More
Mar 2013 $2500.00
2014 Deep Research Report on China Influenza Vaccine Industry
By QYResearch
<2014 Deep Research Report on China Influenza Vaccine Industry > was a professional and depth research report on China Influenza Vaccine Industry. Firstly the report describes the background kno ...Read More
Jan 2014 $2200.00
2014 Strategies for the Adenovirus Diagnostic Testing Market
By Venture Planning Group
The report presents a detailed analysis of the Adenovirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Adenovirus definition, epi ...Read More
Feb 2014 $4350.00
2014 Strategies for the Aeromonads Diagnostic Testing Market
By Venture Planning Group
The report presents a detailed analysis of the Aeromonads diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Aeromonads definition, epi ...Read More
Feb 2014 $4350.00
2014 Strategies for the Campylobacter Diagnostic Testing Market
By Venture Planning Group
The report presents a detailed analysis of the Campylobacter diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Campylobacter definitio ...Read More
Feb 2014 $4350.00
2014 Strategies for the Chancroid Diagnostics Testing Market
By Venture Planning Group
The report presents a detailed analysis of the Chancroid diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Chancroid definition, epide ...Read More
Feb 2014 $4350.00
2014 Strategies for the Chlamydia Diagnostic Testing Market
By Venture Planning Group
The report presents a detailed analysis of the Chlamydia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Chlamydia definition, epide ...Read More
Feb 2014 $4350.00
2014 Strategies for the Clostridium Diagnostic Testing Market
By Venture Planning Group
The report presents a detailed analysis of the Clostridium diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Clostridium definition, e ...Read More
Feb 2014 $4350.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z